Skip to main content
. 2021 Dec 17;2(6Part B):733–741. doi: 10.1016/j.hroo.2021.08.008

Figure 2.

Figure 2

Temporal effects of dantrolene (Dan) on fractional shortening (FS) following doxorubicin (Dox) treatment. A: Effects of Dan 10 mg/kg daily on FS following Dox treatment. Echocardiography was performed at baseline, after day 7 of Dan treatment, and 1, 2, 3, and 4 weeks after Dox treatment. FS was significantly reduced 1 week following the Dox administration and sustained up to the observation period of 4 weeks. Treatment with Dan prevented the decline in FS after Dox treatment. Asterisk (∗) indicates significant differences at 1 week after the injection of Dox (P = .0009 control vs Dox only; P = .04 Dox vs Dan + Dox), 2 weeks after the injection of Dox (P < .0001 control vs Dox only; P < .0001 Dox vs Dan + Dox), 3 weeks after the injection of Dox (P = .0005 control vs Dox only; P = .001 Dox only vs Dan + Dox), and 4 weeks after the injection of Dox (P = .001 control vs Dox; P = .002 Dox vs Dan + Dox). N = 4–5 mice per group. B: Representative images of M-mode echocardiography at 4 weeks after Dox treatment. C: Effects of Dan at 2 and 4 weeks following Dox treatment. FS as measured by echocardiography in the 4 groups. Asterisk (∗) denotes significant difference vs controls (P < .0001 at 2 weeks and P = .001 at 4 weeks after Dox injection) and ¥ denotes significant difference vs Dox group (P < .0001 at 2 weeks and P = .002 at 4 weeks after Dox injection). N = 4–5 mice per group.